Doheny Asset Management Has Cut Its Gilead Sciences (GILD) Position, Kindred Biosciences (KIN)’s Sentiment Is 1.17

June 20, 2017 - By wolcottdaily

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The company has market cap of $159.73 million. The Firm is focused on developing therapies for pets. It currently has negative earnings. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses.

Doheny Asset Management decreased Gilead Sciences Inc (GILD) stake by 8.64% reported in 2016Q4 SEC filing. Doheny Asset Management sold 5,370 shares as Gilead Sciences Inc (GILD)’s stock declined 8.05%. The Doheny Asset Management holds 56,761 shares with $4.07 million value, down from 62,131 last quarter. Gilead Sciences Inc now has $84.85B valuation. The stock declined 0.91% or $0.59 reaching $64.23 per share. About 6,193 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since June 20, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 27 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 9 Hold. Therefore 67% are positive. Gilead Sciences had 65 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, April 29 by UBS. The firm has “Neutral” rating by Citigroup given on Wednesday, February 8. The firm has “Outperform” rating given on Wednesday, July 29 by Oppenheimer. The firm has “Hold” rating given on Tuesday, July 26 by Needham. The stock has “Hold” rating by Jefferies on Wednesday, September 9. The firm has “Neutral” rating by Atlantic Securities given on Friday, December 18. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by BMO Capital Markets on Wednesday, November 2. Stifel Nicolaus initiated Gilead Sciences, Inc. (NASDAQ:GILD) rating on Monday, November 14. Stifel Nicolaus has “Buy” rating and $100 target. On Wednesday, February 3 the stock rating was maintained by Credit Suisse with “Outperform”. The firm earned “Hold” rating on Friday, April 29 by Maxim Group.

Since January 3, 2017, it had 0 buys, and 11 insider sales for $33.68 million activity. $668,667 worth of stock was sold by Cogan John Francis on Tuesday, May 9. Shares for $325,114 were sold by Alton Gregg H. On Wednesday, February 1 the insider MARTIN JOHN C sold $5.32 million. WILSON GAYLE E sold $1.41 million worth of stock.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on July, 24. They expect $2.13 EPS, down 29.70% or $0.90 from last year’s $3.03 per share. GILD’s profit will be $2.81 billion for 7.54 P/E if the $2.13 EPS becomes a reality. After $2.20 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -3.18% negative EPS growth.

Investors sentiment decreased to 0.7 in 2016 Q4. Its down 0.23, from 0.93 in 2016Q3. It fall, as 106 investors sold GILD shares while 656 reduced holdings. 111 funds opened positions while 421 raised stakes. 950.84 million shares or 0.69% more from 944.29 million shares in 2016Q3 were reported. United Cap Financial Advisers Ltd Llc reported 234,521 shares or 0.16% of all its holdings. Centre Asset Ltd owns 1.01% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 73,185 shares. The Pennsylvania-based Private Wealth Advsr has invested 0.43% in Gilead Sciences, Inc. (NASDAQ:GILD). Welch Gp Llc has 0.04% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Cg Asset Mngmt Ltd Limited Liability Company invested in 31,550 shares. First Tru Advsr Limited Partnership invested in 554,804 shares. Lucas Cap Mngmt accumulated 9,095 shares. Bluefin Trading Ltd Liability Co invested in 0.06% or 12,820 shares. Bellecapital Ltd holds 0.4% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 6,250 shares. Bedell Frazier Invest Counseling Ltd Liability Company has 1.59% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Murphy Mgmt holds 0.11% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 9,995 shares. Davenport Ltd Limited Liability Company reported 15,948 shares. 8,171 were accumulated by Atlas Browninc. Ipswich Investment Mngmt reported 30,356 shares. Denver Inv Advsr Ltd Liability Com has 0.02% invested in Gilead Sciences, Inc. (NASDAQ:GILD).

Analysts await Kindred Biosciences Inc (NASDAQ:KIN) to report earnings on August, 14.

About shares traded. Kindred Biosciences Inc (KIN) has risen 71.15% since June 20, 2016 and is uptrending. It has outperformed by 54.45% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: